News Image

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Provided By GlobeNewswire

Last update: May 8, 2025

Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUFA Date

  CALM-CAH Phase 3 Study of Atumelnant for the Treatment of Adults with Congenital Adrenal Hyperplasia to Initiate with Uncompromising Primary Endpoint to Normalize Androstenedione Levels with Physiologic Glucocorticoid Replacement

Read more at globenewswire.com

CRINETICS PHARMACEUTICALS IN

NASDAQ:CRNX (6/11/2025, 8:00:01 PM)

After market: 32.33 0 (0%)

32.33

-0.75 (-2.27%)



Find more stocks in the Stock Screener

Follow ChartMill for more